To explore whether the antitumour effect of SC66 is achieved by inhibiting the AKT signalling pathway, we used Western blotting to detect the expression levels of proteins, including AKT, GSK‐3β, β‐catenin and their respective phosphorylated forms, in BC cells treated with different concentrations of SC66. The gene discussed is GSK3B; the disease is breast cancer.